This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Paratek Pharmaceuticals Croissance future
Future contrôle des critères 4/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Paratek Pharmaceuticals.
Informations clés
73.2%
Taux de croissance des bénéfices
72.9%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 23.7% |
Taux de croissance des recettes | 13.8% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 07 Aug 2023 |
Mises à jour récentes de la croissance future
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2025 | 221 | 2 | -9 | N/A | 2 |
12/31/2024 | 218 | -14 | 30 | N/A | 3 |
12/31/2023 | 163 | -46 | -10 | N/A | 2 |
6/30/2023 | 177 | -63 | -23 | -23 | N/A |
3/31/2023 | 167 | -66 | -36 | -36 | N/A |
12/31/2022 | 160 | -64 | -66 | -66 | N/A |
9/30/2022 | 117 | -89 | -66 | -66 | N/A |
6/30/2022 | 111 | -86 | -27 | -27 | N/A |
3/31/2022 | 139 | -59 | -46 | -46 | N/A |
12/31/2021 | 130 | -59 | -49 | -48 | N/A |
9/30/2021 | 114 | -52 | -53 | -52 | N/A |
6/30/2021 | 104 | -54 | -108 | -107 | N/A |
3/31/2021 | 55 | -87 | -95 | -95 | N/A |
12/31/2020 | 47 | -97 | -104 | -103 | N/A |
9/30/2020 | 40 | -99 | -116 | -115 | N/A |
6/30/2020 | 30 | -111 | -115 | -114 | N/A |
3/31/2020 | 23 | -121 | -129 | -129 | N/A |
12/31/2019 | 17 | -129 | -134 | -134 | N/A |
9/30/2019 | 25 | -124 | -118 | -117 | N/A |
6/30/2019 | 21 | -124 | -110 | -110 | N/A |
3/31/2019 | 19 | -120 | -98 | -98 | N/A |
12/31/2018 | 17 | -112 | -81 | -81 | N/A |
9/30/2018 | 5 | -111 | -85 | -85 | N/A |
6/30/2018 | 5 | -101 | -80 | -80 | N/A |
3/31/2018 | 13 | -89 | -73 | -73 | N/A |
12/31/2017 | 13 | -89 | -80 | -79 | N/A |
9/30/2017 | 8 | -94 | -82 | -80 | N/A |
6/30/2017 | 8 | -96 | -95 | -94 | N/A |
3/31/2017 | 0 | -108 | N/A | -101 | N/A |
12/31/2016 | 0 | -112 | N/A | -94 | N/A |
9/30/2016 | N/A | -106 | N/A | -86 | N/A |
6/30/2016 | N/A | -106 | N/A | -78 | N/A |
3/31/2016 | N/A | -91 | N/A | -70 | N/A |
12/31/2015 | N/A | -71 | N/A | -55 | N/A |
9/30/2015 | 4 | -61 | N/A | -49 | N/A |
6/30/2015 | 4 | -42 | N/A | -30 | N/A |
3/31/2015 | 4 | -29 | N/A | -18 | N/A |
12/31/2014 | 4 | -20 | N/A | -19 | N/A |
9/30/2014 | 0 | -12 | N/A | -9 | N/A |
6/30/2014 | 1 | -11 | N/A | -8 | N/A |
3/31/2014 | 0 | -11 | N/A | -8 | N/A |
12/31/2013 | 0 | -11 | N/A | -6 | N/A |
9/30/2013 | 1 | -37 | N/A | -9 | N/A |
6/30/2013 | 1 | -41 | N/A | -11 | N/A |
3/31/2013 | 3 | -45 | N/A | -10 | N/A |
12/31/2012 | 3 | -50 | N/A | -12 | N/A |
9/30/2012 | 4 | -28 | N/A | -12 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Bénéfices vs marché: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: PRTK is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: PRTK's revenue (13.8% per year) is forecast to grow faster than the US market (7.7% per year).
Croissance élevée des revenus: PRTK's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time